Analystreport

CELYAD SA/ADR (NASDAQ: CYAD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating.

Celyad Oncology SA - American Depositary Shares  (CYAD) 
US:NASDAQ Investor Relations: celyad.com/en/investors